Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with AFib.
Zacks Investment Research on MSN
Abbott stock may benefit following Volt PFA's FDA approval
Abbott Laboratories ABT recently received FDA approval for its Volt PFA System to treat patients battling atrial fibrillation (AFib). The company is expected to begin commercial PFA cases in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback